Introduction

Ghrelin is a potent anabolic molecule with orexigenic and adipogenic actions. This hormone is produced in the periphery, mainly by the stomach but also by lower parts of the gastrointestinal tract [1,2,3]. The peripherally-produced ghrelin reaches the central nervous system via the activation of the vagus nerve. Within the central nervous system, ghrelin activates specific hypothalamic areas connected with the orexins neuropeptide Y, orexin, and Agouti-related peptide [4,5] and regulates growth hormone (GH) secretion and energy homeostasis [6]. Ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a) is located in the hypothalamus, nodose ganglia and gastrointestinal tract and its activation reduces energy expenditure, stimulates food intake and promotes gluconeogenesis and adipose tissue deposition [2,7,8]. In addition, feeding status appears to determine plasma ghrelin levels in humans [1]. However, the orexigenic actions of ghrelin administration are mainly known in the context of an equilibrated energetic balance but little is known about the role of this hormone in different feeding status where the energy intake is not equal to the energy expenditure.

Similar to ghrelin, the endogenous cannabinoid system (ECS) plays a major role in feeding control, energy homeostasis and metabolism [9,10,11,12]. Both peripheral and central mechanisms for the ECS-mediated control of feeding have been described. The ECS controls food intake by a complex network of interactions with a wide variety of peptides or hormones, including orexin A-hypocretin 1 [13,14,15], cholecystokinin [16], oxytocin [17], leptin [18], and the melanocortin [19,20] and opioid [21,22] systems.

Additionally, a functional relationship between central ghrelin and CB1 receptors has also been described, suggesting that the interplay between both systems may take place in the hypothalamic paraventricular nucleus [23,24]. However, whether ECS and ghrelin may interplay also at a peripheral level is unknown.

Blockade of the CB1 receptors emerged as a potential valuable tool for the treatment of diet-induced obesity since chronic pharmacological blockade of CB1 receptors decreases food intake, body weight and improves lipid metabolism not only in...
animal models of obesity but also in humans [25,26]. According to this beneficial profile, the CB1 antagonist SR141716A (Rimonabant, Acomplia®) was translated into therapy for humans [27]. Unfortunately, blockade of CB1 receptors was found to decrease food intake but also to induce central side effects such as depression [28] and, as a consequence, the compound was finally withdrawn from the market due to important psychiatric side effects [29].

Because peripheral CB1 receptors may control appetite while no inducing anxiety [36], we further investigated whether peripheral-acting CB1 receptor antagonists may modulate other signals controlling appetite such as ghrelin. In this study we aim to determine the role of central ghrelin on food intake in rats under different metabolic status and investigate the functional interaction between ghrelin and the ECS, with emphasis in the peripheral nervous system activation [16]. This c-fos expression in brainstem areas was attenuated after higher doses of SR141716A, indicating a dose-dependent peripheral versus central actions of SR141716A [16]. In the last years, peripheral-restricted CB1 antagonists have been developed and tested for feeding inhibition [36,37].

Because peripheral CB1 receptors may control appetite while no inducing anxiety [36], we further investigated whether peripheral-acting CB1 receptor antagonists may modulate other signals controlling appetite such as ghrelin. In this study we aim to determine the role of central ghrelin on food intake in rats under different metabolic status and investigate the functional interaction between ghrelin and the ECS, with emphasis in the peripheral nervous system activation [16]. This c-fos expression in brainstem areas was attenuated after higher doses of SR141716A, indicating a dose-dependent peripheral versus central actions of SR141716A [16]. In the last years, peripheral-restricted CB1 antagonists have been developed and tested for feeding inhibition [36,37].

Materials and Methods

Ethic statement

The protocols for animal care and use were approved by the appropriate Committee of the Ethics of Animal Experiments of the Complutense University. Furthermore, all experimental procedures were carried out according to the European Communities Council Directive of 22 July 2003 (2003/65/CE) and current Spanish regulations of animal research (Real Decreto 1201/2005, BOE 21–10–2005). All efforts were made in order to minimize the number and suffering of the animals used.

Animals

Experimental subjects were a total of 171 adult male Wistar rats (Harlan Ibérica, Madrid, Spain) weighting approximately 250–270 g on the beginning of experiments and housed individually. The animals were acclimated to the facility and handled before any experiment. Rats were kept at constant room temperature (22±1°C) and relative humidity (52±2%) in a 12 h light/dark cycle (lights on at 7:00 am) and had free access to water. The majority of the experiments were started around 11 am. Free-feeding animals had free access to standard pellets of food; fasted rats were totally deprived for food during 24 h before the experiment; and chronic food-restricted rats were limited daily for food intake until body weights reached 80% of free-feeding values (20–25 days). When body weights reached the target value, the amount of food was adjusted daily to maintain a constant body weight. Standard pellets were presented to the rats and food consumption was evaluated at different time points after the beginning of food presentation. The nutritional composition of the regular diet for rats was 16.10% crude protein, 3.10% crude fat, 5.10% crude ash, 3.90% crude fibre, and a pre-mixture of vitamins and minerals, dicalcium phosphate and calcium carbonate. Body weight and water intake were also evaluated before and after food tests. The number of animals per group was 9 rats for each treatment in each condition.

Surgery

Rats were anesthetized with equithesin (3 mg/kg) and unilaterally implanted with a stainless-steel guide cannula (22-G, Nessler, Spain) for intracerebroventricular (i.c.v.) injections. Cannula was aimed at the right or left brain lateral ventricle and stereotaxically implanted according to coordinates determined from the rat brain atlas of Paxinos and Watson (1998) [38] (−0.92 mm antero-posterior; ±1.4 mm lateral to bregma, and 2.8 mm below the skull surface). The injector extended 1 mm beyond the end of the guide cannula. Animals were allowed 9 days post-operative recovery prior to any experimental manipulation. Extensive details on the methods have been published elsewhere [35].

Drugs and treatments

Ghrelin (Tocris, Madrid, Spain) was dissolved in saline (99%) and dimethylsulfoxide (DMSO) (1%) and was administrated i.c.v. in brain lateral ventricle (0.25, 0.5 or 1 µg in 5 µl during 30 s) following a between-subject design with repeated measures at different time points. To ensure complete dispersal of the treatment we kept the injector in situ for additional 30 s.

SR141716A ([N-piperidino-5-(4-chlorophenyl)-1-[2,4-dichlorophenyl]-4-methylpyrazole-3-carboxamide or Rimonabant) was kindly provided by Sanofi Recherche (Montpellier, France) and LH-21 [3-(4-chlorophenyl)-1-[2,4-dichlorophenyl]-3-hexyl-1H-1,2,4-triazole] was synthesized in our laboratory as described before [39]. Both SR141716A and LH-21 were suspended in a vehicle containing Tween 80 (1%) and saline (99%) and administrated by intraperitoneal injection in a volume of 1 ml/kg prior to the i.c.v. injection of ghrelin or vehicle.

Rats received three habituation i.c.v. injections and two intraperitoneal injections (saline) before any treatment.

Statistical analysis

Statistical analyses were performed using SPSS statistical package version 11.0 to Windows or GraphPad Prism (version 5.0) software. A three-way analysis of variance (ANOVA) was performed with three variables: metabolic status (between subjects) x ghrelin dose (between subjects) x time (within subjects). The two-way ANOVAs were performed followed by a Bonferroni post hoc test. All data are presented as mean ± standard errors of the mean and P<0.05 was considered statistically significant.
Results

Effect of i.c.v. ghrelin administration on food intake in rats with different metabolic status

We tested whether treatment with ghrelin (0, 0.25, 0.5 or 1 μg i.c.v.) increased feeding in animals under different metabolic status: animals ad lib fed (free feeding animals), food-deprived for 24 hours (fasted), and chronic food-restricted rats (n = 9 per group) at different time points (60 min and 120 min) post treatment. A 3-way ANOVA (metabolic status x ghrelin dose x time) revealed no overall interaction among the three factors (F(6,96) = 0.44, P = 0.85). However, the test of between-subject effects revealed an interaction between the metabolic status and the dose of ghrelin (F(6,96) = 7.15, P = 0.0001), being ghrelin treatment effective in free feeding animals but not in fasted or chronically deprived animals. The test of within-subject contrast revealed no effect of time and ghrelin doses (F(3,96) = 0.28, P = 0.84) but an overall interaction between time and metabolic status (F(2,96) = 10.79, P = 0.0001), being the time after food presentation more influencing in those conditions where the animals were restricted for food. A comparison among vehicle-injected rats in each condition using two-way ANOVA revealed an interaction between metabolic status and time (F(2,24) = 5.45, P = 0.001), and main effects of time (F(1,24) = 21.23, P = 0.0001), and metabolic status (F(2,24) = 191.4, P<0.0001). A Bonferroni post hoc test indicated significant differences among the control groups in each metabolic condition, consuming more food the chronically food-restricted rats, followed by the fasted group and free feeding rats, respectively.

A detailed analysis of the free feeding condition using a two-way ANOVA revealed a main effect of ghrelin dose (F(2,66) = 4.54, P = 0.01), and main effects of time (F(1,66) = 21.23, P = 0.0001), and metabolic status (F(2,66) = 191.4, P<0.0001). A Bonferroni post hoc test indicated significant differences among the control groups in each metabolic condition, consuming more food the chronically food-restricted rats, followed by the fasted group and free feeding rats, respectively.

No changes in water intake were found in any group tested (data not shown).

EC50 of a dose-response curve of SR141716A on food intake and anxiety

We calculated the maximal effective concentration (EC50) of the CB1 antagonist SR141716A on food intake and anxiety (Fig. 2) by re-analysis of previous data published in [30]. The dose-response curves of SR141716A follow an inverted pattern for feeding and anxiety behaviors, being the EC50 for both conditions 2.2 mg/kg and 2.3 mg/kg, respectively. Taken these data into account, we choose an ultra-low SR141716A dose of 0.03 mg/kg (75 folds lower than the EC50) for our behavioral studies to test the effect of a subthreshold and subanorectic dose of this CB1 antagonist on ghrelin-induced hyperphagia. Therefore, this dose of SR141716A has nule effects on food inhibition and induction of anxiety (Fig. 2). Previous investigations provided evidence for a dose-dependent effect of SR141716A, being low doses effective for peripheral activation whereas highest doses clearly act at central level [16]. Consequently, the ultra-low dose of SR141716A chosen in this study allowed us to test the interaction between ghrelin and CB1 receptors at a peripheral level, as done elsewhere (Crespo I. et al., 2008).

An ultra-low dose of SR141716A and the peripheral CB1 antagonist LH-21 both counteract ghrelin-induced orexigenic actions in free feeding animals

Since ghrelin has orexigenic activity only in free feeding animals we choose this condition to test the effect of a subthreshold dose of SR141716A on ghrelin-induced hyperphagia (Fig. 3A). Free feeding animals were pre-treated with an ultra-low dose of SR141716A (0.03 mg/kg, i.p.) 10 min before the i.c.v. injection of the maximal ghrelin effective dose (0.5 μg) inducing feeding. SR141716A dose was selected based on its Ki for feeding and anxiety behaviors ([13]; and this paper). A two-way ANOVA revealed no interaction (within factors time and treatment (F(6,96) = 0.12), no effect of time (F(1,66) = 2.64), but there was an overall effect of treatment (F(3,66) = 14.90). The Bonferroni post hoc analysis showed that ghrelin increases feeding compared with vehicle at 60 min (P<0.01) and 120 min post-treatment (P<0.001). Pre-treatment with the non-anorectic dose of SR141716A counteracted the orexigenic effects of ghrelin 60 min (P<0.01) and 120 min (P<0.001) post-administration. As expected, the ultra-low dose of 0.03 mg/kg of SR141716A produced no significant differences on food intake versus vehicle-treated animals (P>0.05) (Fig. 3A). No change was found either on body weight or water intake in those animals (data not shown).

Additionally, free feeding animals were pretreated with systemic injections of the peripheral CB1 antagonist LH-21 (3.0 mg/kg, i.p.) 15 min before an i.c.v. injection of ghrelin (0.5 μg, i.c.v.) (Fig. 3B). A two-way ANOVA revealed no interaction (F(3,37) = 0.36) but an overall effect of treatment (F(3,37) = 12.26) and time (F(1,37) = 11.43). The post hoc test indicate that ghrelin treatment increases feeding at 60 min (P<0.01) and 120 min post-treatment (P<0.001) compared with vehicle-injected animals. LH-21 pretreatment blocked the orexigenic effects of ghrelin in free feeding animals 60 min (P<0.01) and 120 min (P<0.001) after injection, and produced no effect on food intake in vehicle-treated animals (P>0.05, n.s.) (Fig. 3B).

Discussion

The main findings of this study are: a) ghrelin-induced orexigenic effects depends on the metabolic status of the animal, being effective in free feeding conditions but having no effect in animals under negative energy balance conditions such as fasted or chronically food-restricted rats; b) blockade of CB1 receptors at extremely low doses (not centrally acting) or with peripheral-restricted CB1 antagonists is able to counteract the hyperphagic effect of central ghrelin administration in free feeding animals. We observed that orexigenic effects of i.c.v. ghrelin administration are only manifested under equilibrate energy balance conditions (free feeding) being ghrelin ineffective in animals with negative energy balance (fasted or chronically food-restricted animals). The increase in food intake after central ghrelin administration occurs rapidly at the first 60 minutes, according to the physiological role of this peptide hormone in meal initiation in humans [40,41]. Feeding status appears to determine plasma ghrelin levels in humans [1]. It is known that total ghrelin levels increase after fasting and are suppressed within minutes by refeeding or enteral nutrient administration [41,42,43]. Specifically, plasma ghrelin levels increase by 31% after 12 h fasting and they are reduced by 22% immediately after feeding [1]. Therefore, plasma ghrelin levels are upregulated under negative energy balance conditions including starvation, whereas they are down-regulated under conditions of positive energy balance [42,43,44]. In line with the aforementioned studies, the lack of ghrelin administration effect in feeding behaviour found in fasted or
chronically food-restricted animals in this study might be explained as the result of a ceiling effect caused by high ghrelin levels during these negative energy balance's states. Indeed, plasma ghelin-like immunoreactivity levels were markedly elevated in patients with anorexia nervosa and negatively correlated with body mass indexes [1]. Alternatively, obese individuals showed decreased levels of total ghrelin as a possible adaptation to the continued negative energy balance ([43]; but see [45]). interesting, energy restriction also modulates CB1 expression in vagal afferent neurons [46], suggesting that metabolic status may influence both ghrelin and endocannabinoid systems which may interact in the control of feeding behavior as discussed later. A detailed understanding of the principles of ghrelin action under different metabolic conditions and its relationship with other peptides systems such as the ECS could be invaluable to understand the physiological role of this hormone controlling appetite.

The role of the ECS in the regulation of food intake has been widely studied in the past few years. However, the relative contribution of central acting versus peripheral ECS in the modulation of food intake and energy balance is still focus of intense research (reviewed in [12,29]). the SR141716A-mediated inhibition of feeding by blockade of CB1 receptors at central level directly correlates with its anxiogenic activity. In this study we show that the EC50 of SR141716A on food inhibition is comparable to its EC50 for induction of anxiety. This fact is actually a handicap for the use of CB1 antagonists in the treatment of obesity and related disorders. According to this, to potentiate the peripheral contribution of CB1 receptors in the control of feeding and energy homeostasis emerges as a valuable alternative to treat obesity, due to the devastating psychiatric side effects found by blocking central CB1 receptors [9,12,29]. In order to test the nature of ghrelin and ECS interaction and the contribution of peripheral CB1 receptors in ghrelin-induced feeding, we choose an ultra-low dose of SR141716A, which is 75 folds lower than the EC50 for inhibition of feeding and, more importantly, for induction of central effects such as anxiety (this paper, and [30]). in our study we showed that an intraperitoneal ultra low-dose of SR141716A is able to counteract the orexigenic effect of i.c.v. ghrelin administration in free feeding animals. This result suggests that there is a powerful cross-talk in vivo between ghrelin and ECS in the modulation of feeding and that this interaction may be occurring at a peripheral level, since low doses of SR141716A are more associated with activation of peripheral sensory terminals whereas higher doses might be related to central effects [16,35]. A functional interaction between ghrelin and ECS has been previously described by others showing that SR141716A (1 mg/kg, i.p.) abolished the orexigenic effect of intra-hypothalamic injection of ghrelin [24]. However, such interaction has been understood as a consequence of a central cross-talk between ghrelin and ECS in hypothalamic areas [23,24]. As presented in Fig. 2 of this paper, the dose of 1 mg/kg of SR141716A (abscesses 0) used in the mentioned paper is a centrally acting dose that reduce feeding effectively and induces anxiety behaviors. Our study shows the effectiveness of a SR141716A ultra-low dose (that neither reduce feeding by itself nor is anxiogenic) on ghrelin-induced hyperphagia.

Figure 1. Effects of ghrelin (0.25 μg, 0.5 μg and 1.0 μg, i.c.v.) on accumulated food intake in free feeding, 24 h food-deprived (fasted) or chronically food-restricted animals 60 min and 120 min after administration. Free-feeding animals (n = 9 in each group) had free access to standard pellets of food; fasted rats (n = 9 in each group) were totally deprived for food during 24 h before the experiment; and chronic food-restricted rats (n = 9 in each group) were limited daily for food intake until body weights reached 80% of free-feeding values (20–25 days). the amount of ingested food in vehicle-injected animals was higher in the food-restricted group, following by the fasted group and free feeding rats, respectively. Ghrelin administration induced hyperphagia at any dose tested exclusively in animals fed ad libitum. no effect of ghrelin administration was observed in fasted or food-restricted animals. Data are means ± SEM of accumulated food intake. Different from free feeding vehicle-injected rats: ***P<0.001. Different from fasted vehicle-injected rats: £££P<0.001. Different from vehicle-injected rats in the same condition (free feeding): *P<0.05. **P<0.01. ***P<0.001.

doi:10.1371/journal.pone.0060918.g001
Additionally, we tested LH-21, a triazol derivative with poor penetration into the central nervous system [37], in the hyperphagia induced by ghrelin in free feeding animals. We previously demonstrated that LH-21 induces appetite reduction in fasted rats and in free feeding animals under standard diet (and even more efficiently under high fat diet) when treated chronically with this peripheral CB1 antagonist [37,47]. Our results in the present study indicate that LH-21 induces no effects in feeding by acute administration in free feeding animals (vehicle-treated rats), but it is highly effective blocking ghrelin-induced hyperphagia in those animals. This latest result, together with the blockade of ghrelin actions by subanorectic doses of SR141716A, suggests that the interplay between ghrelin and ECS may involve peripheral CB1 receptors. Some evidences for a peripheral influence of CB1 receptors on ghrelin actions have also been documented, giving some insight into our results. First of all, blockade of peripheral CB1 receptors decreases central actions of ghrelin such as ghrelin-induced growth hormone secretion, by a CB1 receptor mediated inhibition of hypothalamic GHRH mRNA expression that requires intact vagal afferent fibers [48]. Secondly, SR141716A reduce circulating plasma ghrelin levels in fed rats suggesting a modulatory control of peripheral CB1 receptors on ghrelin secretion by the gastrointestinal tract [49]. Thirdly, CB1 receptors and GHS-R1a receptors are both expressed in the nodose ganglia [7,46,50] and, precisely, intact vagal afferents neurons appears to be required for the orexigenic effects of ghrelin [50,51,52] and the anorectic effect of SR141716A ([35], but also see [53]). Whether both CB1 and GHS-R1 receptors co-localize anywhere in the ascending pathways from the periphery to the hypothalamus is still unknown, although both ghrelin and ECS appears to modulate the intracellular AMP-activated protein kinase in peripheral tissues and in the hypothalamus [54,55]. It is possible that CB1 receptors and GHS-R1a receptor co-localize en the vagus nerve (and even in the hypothalamus) to modulate the same intracellular pathway. In this case, ghrelin and endocannabinoids may show an orexigenic synergic effect due to a signal amplification of one to the other in a

![Figure 2. EC50 of a dose-response curve of SR141716A on food intake and anxiety.](A) effect of SR141716A (0, 0.1, 1.0 and 3.0 mg/kg, i.p.) on responses for food; B) effect of SR141716A (0, 0.1, 1.0 and 3.0 mg/kg, i.p.) on anxiety, expressed as latency to emerge a defensive withdrawal behaviour. The figures represent a re-analysis of the data previously published [30]. The half maximal effective concentration (EC50) is 2.2 mg/kg and 2.3 mg/kg for food inhibition and induction of anxiety behavior, respectively. doi:10.1371/journal.pone.0060918.g002

![Figure 3. Pretreatment with an ultra-low dose of SR141716A or the peripheral CB1 antagonist LH-21 on the orexigenic effect induced by ghrelin in free feeding animals.](A) The subeffective dose of SR141716A (0.03 mg/kg, i.p) counteracted ghrelin-induced orexigenic effect. As expected, the ultra-low dose of SR141716A showed no effect on food intake in vehicle-treated animals. B) Pretreatment with LH-21 (3 mg/kg, i.p.) counteracted the increase in food intake induced by ghrelin and had no effect in vehicle-treated rats. Data are means ± SEM of 6–10 determinations per group. Different from vehicle-injected rats: *P<0.05, **P<0.01; different from ghrelin treatment: *P<0.05, **P<0.01, ***P<0.001. doi:10.1371/journal.pone.0060918.g003
Peripheral CB1 Antagonism on Ghrelin Actions

In our study we can not exclude that the ECS-ghrelin interaction takes place directly in hypothalamic areas. Within the hypothalamus, one of the main areas involved in energy balance regulation, CB1 receptors are expressed in the arcuate nuclei, the paraventricular nuclei and the lateral hypothalamic area [60,61] and GHS-R1a receptors are expressed in paraventricular, dorsomedial and ventromedial nucleus and arcuat [9,62]. Interestingly, hypothalamic areas containing CB1 and GSH-R1 receptors such as the arcuate nuclei are not completely protected by the blood brain barrier because of its crucial role for the regulation of energy homeostasis [63]. It is to note that hypothalamic CB1 receptors are expressed in a relative low quantity levels but its targeting shows a high efficiency functional correlate [64]. It is possible then that the CB1 receptor interaction with other peptide systems/hormones such as ghrelin is responsible of such functional efficiency in the hypothalamus. Nevertheless, although the openings in the blood brain barrier might suggest a hypothalamic interaction the lack of activity of LH-21 or SR151716A at the doses used in this study in the HHA axis or inducing anxiety [30,36] weakens this hypothesis.

Taken together, our results show that ghrelin acts differently according to the metabolic status of the animal, inducing hyperphagia in free feeding animals but not in rats under negative metabolic conditions. Our study also suggests that the behavioral interaction between ghrelin and CB1 receptors in the control of food intake may occur at the peripheral level and, therefore, we propose that there is still a future for novel CB1 antagonists unable to cross the blood-brain barrier to counteract the orexigenic signal when ghrelin is overactivated.

Author Contributions

Conceived and designed the experiments: LO RG FRF. Performed the experiments: FA IC MTRL LO RG. Analyzed the data: FA IC RG LO. Contributed reagents/materials/analysis tools: NJ PG FRF LO RG. Wrote the paper: LO FRF.

References

1. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, et al. (2001) Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86: 4755-4758.
2. Koijina M, Hosoda H, Date Y, Nakazato M, Matsuo H, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
3. Sakata I, Nakamura K, Yamazaki M, Matsubara M, Hayashi Y, et al. (2002) Ghrelin-producing cells exist as two types of cells, closed- and open-type cells, in the rat gastrointestinal tract. Peptides 23: 531-536.
4. Kamogai T, Tamura H, Shimizu T, Ishii S, Sugihara H, et al. (2001) Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 50: 2438-43.
5. Nakazato M, Murakami N, Date Y, Koijina M, Matsuo H, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194-8
6. Popovic V, Mitjic D, Micic D, Damjanovic S, Arvat E, et al. (2003) Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 88: 3450-3453.
7. Burtyga G, Yarro A, Dimaline R, Thompson DG, Dockray GJ (2006) Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol. 290: G2136-97.
8. Gnan XM, Yu H, Palyha OC, McKeen KK, Feiglner SD, et al. (1997) Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48: 23-29.
9. Bermudez-Silva FJ, Cardinal P, Cota D (2012) The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol. 26: 114-24
10. Di Marzo V, Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589.
11. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
12. Viveros Mp, de Fonseca FR, Bermudez-Silva FJ, McPartland JM (2008) Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets. 8: 220-30.
13. Crespo I, Gomez de Heras R, Rodriguez de Fonseca F, Navarro M (2008) Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology 54: 219-225.
14. Ellis J, Peddani JD, Canals M, Milanta S, Milligan G (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281: 30812-30824.
15. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P (2003) Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716E. J Biol Chem 278: 23731-23737.
16. Oriz L, Crespo I, Lopez-Moreno JA, Reyes-Cabello C, Rodriguez de Fonseca F, et al. (2011) Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. Pharmacol Biochem Behav. 98: 220-6.
17. Vertty AN, McFarlane JR, McGregor IS, Mallet PE (2004) Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 47: 593-603.
18. Di Marzo V, Goparaju SK, Wang L, Liu J, Bakai S, et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825.
19. Matias I, Vergoni AV, Petrosino S, Ottani A, Pocai A, et al. (2008) Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology 54: 206-212.
20. Vertty A, McFarlane JR, McGregor IS, Mallet PE, et al. (2004) Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 145: 3224-3231.
21. Kirkham TC, Williams CM (2001) Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl) 153: 267-270.
Peripheral CB1 Antagonism on Ghrelin Actions

22. Navarro M, Carrera MR, Fratta W, Valverde O, Cousu G, et al. (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344-5350.

23. Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, et al. (2006) The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 3: 797.

24. Tucci SA, Rogers EK, Korbonits M, Kirkham TC (2004) The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. J Pharmacol 143: 520-528.

25. Cota D (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23: 567-17.

26. Di Marzo, Desprez JP (2009): CB1 antagonists for obesity—what lessons have we learned from rimonabant? Nat Rev Endocrinol 5(11): 633-8.

27. Van Gaal LF, Rissanen AM, Schern AJ, Ziegler O, Rossner S (2005): Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397.

28. Moreira FA, Crippa JA (2008): The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr. 31: 145-53.

29. Bermúdez-Silva EJ, Viveros MP, McPartland JM, Rodríguez de Fonseca F (2010): The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 93: 373-382.

30. Navarro M, Hernandez E, Mansue RM, del Arco I, Villanua MA, et al. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 8: 491-6.

31. Bermúdez-Silva EJ, Suarez J, Baixeras E, Cobo N, Bautista D, et al. (2008) Presence of functional cannabinoid receptors in human pancreas. Diabetologia 51: 476-87.

32. Hornby PJ, Prousy SM (2004) Involvement of cannabinoid receptors in gut motility and visceral perception. 141: 1335-45.

33. Kunos G, Tam J (2011) The case for peripheral CB receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 163: 1423-31.

34. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100.

35. Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, et al. (2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22: 9612-9617.

36. Pavon FJ, Bilbao A, Hernandez-Folgado I, Cippitelli A, Jagerovic N, et al. (2008) Peripheral endocannabinoid system-mediated actions of rimonabant on growth hormone secretion are ghrelin-dependent. J Neuroendocrinol 22: 1127-36.

37. Hornby PJ, Prousy SM (2004) Involvement of cannabinoid receptors in gut motility and visceral perception. 141: 1335-45.

38. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. IV Edition. Academic Press.

39. Research Committee of the Gastrin, GIP and Other Gastrointestinal Hormones. (1981) Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus. Mol Endocrinol 5: 358-366.

40. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelet D (2004) Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 287: E297-304.

41. Cummings DE, Purnell JQ, Frayo RS, Schmidlova K, Wisse BE, et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714-1719.

42. Toshihisa K, Mondal MS, Nakazato M, Date Y, Murakami N, et al. (2001) Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 281: 1220-1225.

43. Tschop M, Wavarta R, Riepl RL, Friedrich S, Biddingmaier M, et al. (2001) Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 24: 18-21.

44. Shiya T, Nakazato M, Minuta M, Date Y, Mondal MS, et al. (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87: 240-4.

45. Rodriguez A, Gomez-Ambrosi J, Catalan V, Gil MJ, Becerril S, et al. (2009) Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 33: 541-52.

46. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, et al. (2000) Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. Cholecystokinin. J Neurosci 24: 7208-15.

47. Finegold AL, Ceballos G, Glicksman AA, Hildesheim AM, et al. (2010) Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleanolactamide. Br J Nutr 92: 757-761.

48. Date Y, Toshinai K, Kodua S, Miyazato M, Shimbara T, et al. (2005) Peripheral interaction of ghrelin with cholecystokinin on feeding regulation. Endocrinology 146: 3518-25.

49. Asakawa A, Inui A, Kaga T, Yuzuruhira H, Nagata T, et al. (2001) Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120: 337-45.

50. Davé Y, Murakami N, Toshinai K, Matsukura S, Nijimu A, et al. (2002) The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123: 1120-9.

51. Madsen An, Jelbing J, van de Wall Eh, Vrang N, Larsen PJ, et al. (2009) Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. Neurosci Lett 449: 20-3.

52. Koh B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, et al. (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280: 25196-25201.

53. van Tuyl H, Kola B, Korbonits M (2008) Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase. Vitam Horm 77: 121-146.

54. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, et al. (2008) mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 108: 308-319.

55. Przybyla JA, Wats VJ (2010) Ligan-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther 332: 710-719.

56. Ward RJ, Pediani JD, Milligan G (2011) Heteromultimerization of cannabinoid CB1 receptor and orexin OX1 receptor generates a unique complex in which both proteins are regulated by orexin A. J Biol Chem 286: 37141-37148.

57. Schellens H, van Oeffelen WE, Dinan TG, Cryan JF (2013) Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signalling. J Biol Chem 288: 181-191.

58. Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168: 299-325.

59. Sin LI, Selley DE, Childs SR (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanyl 5'-[gamma-35S]-triphosphate binding. Proc Natl Acad Sci U S A 92: 7243-7246.

60. Mondal MS, Date Y, Yamaguchi H, Toshinai K, Tsuruta T, et al. (2005) Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus. Regul Pept 126: 53-9.

61. Merchenthaler I (1991) Neurons with access to the general circulation in the central nervous system of the rat: a retrograde tracing study with fluoro-gold. Neuroscience 44: 653-662.

62. Breivogel CS, Childs SR (1998) The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 5: 417-431.